Complete response in metastatic breast cancer with visceral crisis using a combination of cyclin-dependent kinase 4/6 inhibitor and aromatase inhibitor: A case report from the eastern region of India

Patients with metastatic breast cancer (MBC) in visceral crisis require systemic chemotherapy. However, a coexisting cardiac failure that contradicts the use of chemotherapy often demands an alternative treatment. Here, we report case hormone-receptor-positive MBC cardiological comorbidities. She was treated combination treatment tablet Ribociclib (600 mg once daily for 21 days followed by 7 gap) and Letrozole (2.5 daily). The patient had complete metabolic response 18-Fluorodeoxyglucose Positron Emission tomography-Computed Tomography (18F-FDG PET/CT), after 6 months Combination is beneficial postmenopausal females hormone receptor-positive human epidermal growth factor receptor 2 neu-negative who have contraindication to